Medesis Pharma Past Earnings Performance
Past criteria checks 0/6
Medesis Pharma's earnings have been declining at an average annual rate of -26%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 13.3% per year.
Key information
-26.0%
Earnings growth rate
-20.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 13.3% |
| Return on equity | n/a |
| Net Margin | -4,924.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Medesis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -3 | 1 | 0 |
| 31 Mar 24 | 0 | -4 | 1 | 0 |
| 31 Dec 23 | 0 | -4 | 1 | 0 |
| 30 Sep 23 | 0 | -3 | 1 | 0 |
| 30 Jun 23 | 0 | -3 | 1 | 0 |
| 31 Mar 23 | 0 | -3 | 1 | 0 |
| 31 Dec 22 | 0 | -3 | 1 | 0 |
| 30 Sep 22 | 0 | -3 | 1 | 0 |
| 30 Jun 22 | 0 | -3 | 1 | 0 |
| 31 Mar 22 | 0 | -3 | 1 | 0 |
| 31 Dec 21 | 0 | -3 | 1 | 0 |
| 30 Sep 21 | 0 | -2 | 1 | 0 |
| 30 Jun 21 | 0 | -2 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 0 | 0 |
Quality Earnings: 76D is currently unprofitable.
Growing Profit Margin: 76D is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 76D is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.
Accelerating Growth: Unable to compare 76D's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 76D is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 76D's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.